NASDAQ:REPL - Replimune Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$12.94 -1.13 (-8.03 %)
(As of 02/19/2019 03:44 PM ET)
Previous Close$14.07
Today's Range$12.76 - $13.88
52-Week Range$8.88 - $23.55
Volume1,023 shs
Average Volume32,741 shs
Market Capitalization$408.31 million
P/E RatioN/A
Dividend YieldN/A
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Receive REPL News and Ratings via Email

Sign-up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:REPL



Sales & Book Value

Annual SalesN/A



Market Cap$408.31 million
OptionableNot Optionable

Replimune Group (NASDAQ:REPL) Frequently Asked Questions

What is Replimune Group's stock symbol?

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

How were Replimune Group's earnings last quarter?

Replimune Group Inc (NASDAQ:REPL) released its quarterly earnings results on Thursday, February, 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.24). View Replimune Group's Earnings History.

When is Replimune Group's next earnings date?

Replimune Group is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Replimune Group.

What price target have analysts set for REPL?

3 brokers have issued 12-month target prices for Replimune Group's shares. Their predictions range from $25.00 to $31.00. On average, they expect Replimune Group's share price to reach $27.3333 in the next twelve months. This suggests a possible upside of 111.2% from the stock's current price. View Analyst Price Targets for Replimune Group.

What is the consensus analysts' recommendation for Replimune Group?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Replimune Group.

Has Replimune Group been receiving favorable news coverage?

Media coverage about REPL stock has trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Replimune Group earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Who are some of Replimune Group's key competitors?

Who are Replimune Group's key executives?

Replimune Group's management team includes the folowing people:
  • Mr. Philip Astley-Sparke, Exec. Chairman, Sec. & Treasurer (Age 48)
  • Dr. Robert Coffin, Pres, CEO & Director (Age 54)
  • Dr. Colin Love, Chief Operating Officer (Age 61)
  • Stephen Gorgol, Chief Accounting Officer
  • Dr. Pamela Esposito, Chief Bus. Officer (Age 45)

When did Replimune Group IPO?

(REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

When did Replimune Group's lock-up period expire?

Replimune Group's lock-up period expired on Wednesday, January 16th. Replimune Group had issued 6,700,000 shares in its IPO on July 20th. The total size of the offering was $100,500,000 based on an initial share price of $15.00. Since the expiration of Replimune Group's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

Who are Replimune Group's major shareholders?

Replimune Group's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.27%), Emerald Advisers LLC (2.06%), Emerald Mutual Fund Advisers Trust (1.99%), Polar Capital LLP (0.55%), Victory Capital Management Inc. (0.40%) and Northern Trust Corp (0.26%). Company insiders that own Replimune Group stock include Fund Iv Gp LP Omega and Joseph P Slattery. View Institutional Ownership Trends for Replimune Group.

Which major investors are selling Replimune Group stock?

REPL stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. View Insider Buying and Selling for Replimune Group.

Which major investors are buying Replimune Group stock?

REPL stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Polar Capital LLP, UBS Oconnor LLC, UBS Oconnor LLC, Geode Capital Management LLC and New York State Common Retirement Fund. Company insiders that have bought Replimune Group stock in the last two years include Fund Iv Gp LP Omega and Joseph P Slattery. View Insider Buying and Selling for Replimune Group.

How do I buy shares of Replimune Group?

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Replimune Group's stock price today?

One share of REPL stock can currently be purchased for approximately $12.94.

How big of a company is Replimune Group?

Replimune Group has a market capitalization of $408.31 million. Replimune Group employs 44 workers across the globe.

What is Replimune Group's official website?

The official website for Replimune Group is

How can I contact Replimune Group?

Replimune Group's mailing address is 18 COMMERCE WAY, WOBURN MA, 01801. The company can be reached via phone at 781-995-2443 or via email at [email protected]

MarketBeat Community Rating for Replimune Group (NASDAQ REPL)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  80
MarketBeat's community ratings are surveys of what our community members think about Replimune Group and other stocks. Vote "Outperform" if you believe REPL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by Staff

Featured Article: Net Income

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel